About Stemgent
Stemgent is a company based in Cambridge (United States) founded in 2008 was acquired by ReproCELL in September 2014. Stemgent has raised $43.23 million across 9 funding rounds from investors including ReproCELL, Morgenthaler and Healthcare Ventures. Stemgent has completed 1 acquisition, including Asterand Bioscience. Stemgent operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$43.23 M (USD)
in 9 rounds
-
Latest Funding Round
$11.3 M (USD), Series B
Aug 06, 2012
-
Investors
ReproCELL
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
ReproCELL
(Sep 08, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Stemgent
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Stemgent
Stemgent has successfully raised a total of $43.23M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $11.3 million completed in August 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stemgent
Stemgent has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ReproCELL, Morgenthaler and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investment firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture.
|
Locked | Locked | Locked |
Investor details for Stemgent
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stemgent
Stemgent has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Asterand Bioscience.
Investment portfolio details for Stemgent
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Human tissue solutions for drug discovery research are supplied globally.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Stemgent
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Stemgent
Detailed financials for Stemgent
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stemgent Comparisons
Peer comparison for Stemgent
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stemgent
Stemgent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Stemgent
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stemgent
Complete news archive for Stemgent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stemgent
Stemgent was founded in 2008.
Stemgent is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Stemgent is a funded company, having raised a total of $43.23M across 9 funding rounds to date.
Stemgent was founded in 2008 in Cambridge, United States, within the biotechnology sector focused on stem cell research. Cellular reprogramming products and tissue-based research tools are provided through a portfolio that includes mRNA systems, cell culture media, antibodies, small molecules, cytokines, and iPS reprogramming services. The Induced Pluripotent Stem Cells business was acquired by ReproCELL USA on October 1, 2014.
Stemgent's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Stemgent has made 1 acquisition, including Asterand Bioscience.
Stemgent has 3 investors. Key investors include ReproCELL, Morgenthaler, and Healthcare Ventures.